BioImagene Announces Board Expansion and Appoints Biotechnology Veteran G Steven...

BioImagene Announces Board Expansion and Appoints Biotechnology Veteran G Steven Burrill as Chairman

CUPERTINO, Calif.--(Business Wire)--
BioImagene, the leading provider of innovative and affordable
digital pathology solutions for cancer diagnosis and pre clinical
research, today announced the appointment of G Steven Burrill as
chairman of the board.

The company also announced the appointment of two new board
members. The new members include Mr. Taras Silecky of Ascension Health
Ventures and Dr. Ajit Singh, CEO of the Image and Knowledge Management
business of Siemens Healthcare who will join as an independent board
member.

These announcements come at the heels of the recent closing of a
$26 million series D financing round led by Burrill & Company,
Ascension Health Ventures, National Healthcare Services as well as
existing investors Artiman Ventures and ICCP Ventures

Mr. Steven Burrill said, "We are delighted to join a distinguished
group of investors and an experienced management team. Digital
pathology, riding on the convergence of innovations in biomarker
discovery, pathology and imaging technology is primed for personalized
medicine supporting our Healthcare Vision 2020."

"We are fortunate to have the insight and experience of Mr.
Burrill, Dr. Singh and Mr. Silecky," said Mohan Uttarwar CEO,
BioImagene. Mr. Uttarwar continued, "Their addition, along with our
world class management team and the infusion of capital will enable
BioImagene extend its dominant position in technology innovation and
business models. We are now prepared for a full scale operation."

Dr Ajit Singh said, "Pathology is poised for the widespread
adoption of technology just as radiology was, ten years ago.
Technology focused companies using digital pathology applications will
experience the inherent value of greater efficiency, productivity and
standardization in pathology workflows. More importantly, there are
some innovations that are possible only in the digital world, such as
use of knowledge-based algorithms, data mining, and decision support."

"Hospitals are entering the digital age and digital pathology is a
major step towards an integrated workflow and EMR. It enables a quick
and efficient exchange of information ultimately improving the speed
and quality of patient care with greater levels of accuracy,"
commented Mr. Taras Silecky.

About BioImagene

BioImagene is a leading provider of total digital pathology
solutions for applications including clinical diagnostics and drug
discovery. BioImagene products are FDA -cleared for specific clinical
applications, and are intended for research use for other
applications. www.bioimagene.com.

BioImagene
Suchi Parth, 408-207-4285

Copyright Business Wire 2008